Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

MorphoSys (Group)

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *

 

Period Start 1992-01-01 established
  Today MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Predecessor Max Planck Society for the Advancement of Science
Product Industry biopharmaceutical
Persons Person Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme)
  Person 2 Holstein, Jens (MorphoSys 201105– CFO before Regional CFO Fresenius Kabi + Managing Director Fresenius Kabi Deutschland)
     
Region Region Martinsried
  Country Germany
  Street 7 Semmelweisstr.
  City 82152 Planegg
  Tel +49-89-89927-0
    Address record changed: 2018-07-24
     
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency EUR
  Annual sales 76,442,505 (revenues, consolidated (2018) 2018-12-31)
  Profit -56,172,121 (2018-12-31)
  Cash 45,459,836 (2018-12-31)
     
    * Document for �About Section�: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg.
     
   
Record changed: 2019-06-25

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top